Profile data is unavailable for this security.
About the company
TuHURA Biosciences, Inc. is a Phase III registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. Its lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It has initiated a single randomized placebo-controlled Phase III registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) compared to Keytruda plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. It is leveraging its Delta Opioid Receptor technology to develop bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. It is also focused on the novel VISTA inhibiting mAb, known as TBS-2025.
- Revenue in USD (TTM)0.00
- Net income in USD-43.77m
- Incorporated2009
- Employees19.00
- LocationTuHURA Biosciences Inc10500 University Center Dr., Suite 110TAMPA 33612United StatesUSA
- Phone+1 (813) 875-6600
- Fax+1 (604) 202-1384
- Websitehttps://tuhurabio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gain Therapeutics Inc | 0.00 | -19.39m | 66.92m | 23.00 | -- | 10.59 | -- | -- | -0.6364 | -0.6364 | 0.00 | 0.1643 | 0.00 | -- | -- | 0.00 | -153.07 | -79.58 | -234.03 | -95.32 | -- | -- | -- | -19,975.78 | -- | -33.79 | 0.067 | -- | -100.00 | -- | 8.34 | -- | 10.39 | -- |
| Coeptis Therapeutics Holdings Inc | 500.99k | -11.28m | 69.09m | 5.00 | -- | 5.97 | -- | 137.91 | -3.47 | -3.47 | 0.1476 | 2.01 | 0.0433 | -- | 11.65 | 100,198.00 | -118.13 | -42.24 | -167.86 | -44.32 | 72.96 | -- | -2,727.81 | -- | -- | -73.66 | 0.0224 | -- | -- | -- | 53.85 | -- | -- | -- |
| XBiotech Inc | 0.00 | -29.16m | 72.26m | 88.00 | -- | 0.4325 | -- | -- | -0.9566 | -0.9566 | 0.00 | 5.48 | 0.00 | -- | -- | 0.00 | -15.25 | -7.74 | -16.08 | -8.02 | -- | -- | -- | -187.68 | -- | -- | 0.00 | -- | -- | -- | -56.90 | -- | 44.92 | -- |
| Nuo Therapeutics Inc | 2.61m | -2.43m | 72.42m | -- | -- | -- | -- | 27.73 | -0.0517 | -0.0517 | 0.0555 | -0.0088 | 1.43 | 4.19 | 5.32 | -- | -133.29 | -121.45 | -289.99 | -243.05 | 70.38 | 78.52 | -93.06 | -424.19 | 1.00 | -17,110.33 | -- | -- | 124.34 | 56.34 | 26.73 | -- | -- | -- |
| Ibio Inc | 500.00k | -20.11m | 76.34m | 20.00 | -- | 0.7988 | -- | 152.68 | -1.44 | -1.44 | 0.0232 | 2.77 | 0.0113 | -- | 15.38 | 25,000.00 | -45.35 | -30.90 | -50.81 | -37.76 | -- | -- | -4,021.60 | -2,374.12 | -- | -- | 0.0127 | -- | 77.78 | -24.57 | -19.00 | -- | -57.50 | -- |
| Medicinova Inc | 257.92k | -12.01m | 78.14m | 13.00 | -- | 1.77 | -- | 302.97 | -0.2449 | -0.2449 | 0.0053 | 0.8964 | 0.0049 | -- | -- | 19,840.00 | -22.73 | -15.56 | -24.08 | -16.17 | -- | -- | -4,656.61 | -1,144.98 | -- | -- | 0.00 | -- | -100.00 | -- | -28.91 | -- | -39.68 | -- |
| TuHURA Biosciences Inc | 0.00 | -43.77m | 78.33m | 19.00 | -- | 4.01 | -- | -- | -1.60 | -1.60 | 0.00 | 0.3273 | 0.00 | -- | -- | 0.00 | -286.97 | -- | -456.76 | -- | -- | -- | -- | -- | -- | -9.01 | 0.0286 | -- | -- | -- | -- | -- | -- | -- |
| ImageneBio Inc | 0.00 | -46.14m | 78.50m | 15.00 | -- | 0.5614 | -- | -- | -8.11 | -8.11 | 0.00 | 12.51 | 0.00 | -- | -- | 0.00 | -29.23 | -29.58 | -31.29 | -33.67 | -- | -- | -- | -407.25 | -- | -- | 0.00 | -- | -100.00 | -- | 27.77 | -- | -- | -- |
| Tenax Therapeutics Inc | 0.00 | -43.33m | 81.17m | 4.00 | -- | 0.7982 | -- | -- | -1.13 | -1.13 | 0.00 | 16.29 | 0.00 | -- | -- | 0.00 | -42.77 | -99.65 | -44.80 | -118.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -128.28 | -- | -- | -- |
| Champions Oncology Inc | 58.42m | 2.49m | 81.93m | 213.00 | 35.40 | 19.65 | 20.60 | 1.40 | 0.1667 | 0.1667 | 4.14 | 0.3003 | 2.11 | -- | 5.31 | 274,291.10 | 8.78 | -4.67 | 33.91 | -11.66 | 50.11 | 47.28 | 4.16 | -2.79 | -- | -- | 0.0327 | -- | 13.54 | 12.13 | 164.61 | -- | -29.41 | -- |
| eXoZymes Inc | 0.00 | -8.34m | 84.00m | 31.00 | -- | 15.61 | -- | -- | -1.76 | -1.76 | 0.00 | 0.6408 | 0.00 | -- | -- | 0.00 | -147.87 | -- | -393.50 | -- | -- | -- | -- | -- | -- | -- | 0.0217 | -- | -- | -- | -187.55 | -- | -- | -- |
| Pyxis Oncology Inc | 2.82m | -97.09m | 84.06m | 44.00 | -- | 1.22 | -- | 29.81 | -1.58 | -1.58 | 0.0457 | 1.11 | 0.0187 | -- | -- | 64,090.91 | -64.53 | -47.22 | -74.33 | -53.45 | 0.00 | -- | -3,442.77 | -2,233.63 | -- | -- | 0.0006 | -- | -- | -- | -4.80 | -- | -- | -- |
| Spruce Biosciences Inc | 697.00k | -47.88m | 88.51m | 9.00 | -- | 8.65 | -- | 126.99 | -84.64 | -84.64 | 1.22 | 9.56 | 0.0173 | -- | -- | 33,190.48 | -119.08 | -43.45 | -161.94 | -49.92 | -- | -- | -6,869.30 | -1,459.77 | -- | -353.48 | 0.091 | -- | -51.32 | -- | -10.68 | -- | -- | -- |
| Immunic Inc | 0.00 | -103.05m | 89.29m | 91.00 | -- | 6.97 | -- | -- | -0.8362 | -0.8362 | 0.00 | 0.1064 | 0.00 | -- | -- | 0.00 | -195.41 | -83.24 | -396.11 | -96.02 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.37 | -- | 36.85 | -- |
Data as of Feb 12 2026. Currency figures normalised to TuHURA Biosciences Inc's reporting currency: US Dollar USD
8.71%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 2.10m | 3.46% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 1.39m | 2.29% |
| Geode Capital Management LLCas of 30 Sep 2025 | 622.77k | 1.03% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 275.54k | 0.45% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 208.37k | 0.34% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2025 | 186.82k | 0.31% |
| The Bank of New York Mellon Corp. (Investment Management)as of 30 Sep 2025 | 182.27k | 0.30% |
| Apollon Wealth Management LLCas of 31 Dec 2025 | 134.29k | 0.22% |
| Suncoast Equity Management LLCas of 30 Sep 2025 | 104.41k | 0.17% |
| Charles Schwab Investment Management, Inc.as of 30 Sep 2025 | 79.03k | 0.13% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
